Saving lives by refining immune responses.

Immune imbalance:
From allergies to GVHD

An imbalanced immune system can lead to a variety of health problems, ranging from mild to life-threatening. Allergies represent the milder end, where an overactive immune response to harmless substances results in inflammation and symptoms like itching or sneezing. A more severe condition is graft-versus-host disease (GVHD), that causes significant morbidity and mortality.

Allogenic hematopoietic stem cell transplantation

Allogeneic hematopoietic stem cell transplantation is a treatment mainly used for blood-related cancers and some other severe diseases. During this process, stem cells from healthy donors are transferred into patient's bodies to replace damaged or diseased cells. While this treatment can be life-saving, it comes with serious risks and complications like GVHD.

Graft-versus-host disease

GVHD is a complex medical condition that often occurs after allogeneic hematopoietic stem cell transplantation. Thereby, the donated stem cells perceive the recipient's body as foreign and initiate an immune response against it, which leads to severe complications and prevents a broader application of these transplantations.

Unleashing the potential of transplantations

We have developed a targeted therapy designed to effectively modulate immune responses. This breakthrough not only has the potential to significantly reduce the risk of complications like GVHD, but also offers promise in treating a wide range of autoimmune and inflammatory diseases. By fine-tuning the immune system's behavior, our solution aims to maximize the benefits of transplantation and other therapies, thereby improving patient outcomes and expanding the scope of treatable diseases.

Our team

At ASH we are a team of renowned scientists and clinicians, dedicated young professionals, complemented by successful serial entrepreneurs.

Initiator & Senior Scientist

Dr. Jörn Albring

Jörn is a physician with training in hematology and oncology and currently works at Universitätsklinikum Münster. He is the inventor and developer of the ASH approach.

Managing Director

Dr. Markus Hannebauer

Markus is a computer scientist by training and serial entrepreneur. At ASH he acts as benevolent layman, angel investor and incubator.

Product Lead

Dr. Lena Hänsch

Lena is a biologist with a background in translational research in academia and industry. She is responsible for product translation and project management.

Market Lead

Dr. Martin Schumacher

Martin has a background in technology management and chemistry. He is responsible for partner management and operations.